Form 8-K - Current report:
SEC Accession No. 0001104659-25-031713
Filing Date
2025-04-03
Accepted
2025-04-03 16:32:07
Documents
16
Period of Report
2025-04-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2511361d2_8k.htm   iXBRL 8-K 29416
2 EXHIBIT 1.1 tm2511361d2_ex1-1.htm EX-1.1 213581
3 EXHIBIT 5.1 tm2511361d2_ex5-1.htm EX-5.1 10264
7 GRAPHIC tm2511361d2_ex5-1img001.jpg GRAPHIC 7360
  Complete submission text file 0001104659-25-031713.txt   495393

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA btai-20250403.xsd EX-101.SCH 3047
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE btai-20250403_lab.xml EX-101.LAB 34239
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE btai-20250403_pre.xml EX-101.PRE 22380
18 EXTRACTED XBRL INSTANCE DOCUMENT tm2511361d2_8k_htm.xml XML 3562
Mailing Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511
Business Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511 203-643-8060
BioXcel Therapeutics, Inc. (Filer) CIK: 0001720893 (see all company filings)

EIN.: 821386754 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38410 | Film No.: 25810075
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)